Chemotherapy in Treating Patients With Lung Cancer (FRAME)

Lilly

Status: Completed

Conditions: Non Small Cell Lung Cancer

Treatments: Drug: Any platinum-based doublet chemotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT01067794

H3E-EW-B012 (Other Identifier)

13095

Details and patient eligibility

About

This observational study was planned, with the primary objective to observe patient survival following first-line treatment of patients of Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) with different platinum-based doublets under routine disease management conditions. Further secondary objectives of this study are to provide insights to what extent histologic subtyping and the use of additional prognostic or predictive biomarkers are currently considered for differential therapeutic decisions under routine conditions. All of these data are critical to evaluate the factors for differential therapeutic decisions and their effect on patient outcomes in a real life setting, and they can only be obtained through observational research.

Enrollment: 1,610 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological or cytological diagnosis of non-small cell lung cancer (NSCLC) stage IIIB-IV
• Initiation of first-line treatment for advanced NSCLC with any platinum-based doublet chemotherapy, with or without additional targeted agents
• 18 years of age or older

Exclusion criteria

• Participating simultaneously in a study including administration of any investigational drug or procedure at entry into this study

Trial design

1,610 participants in 5 patient groups

pemetrexed + platinum

Description:

Patients with pemetrexed + platinum doublet, with or without additional targeted agents

Treatment:

Drug: Any platinum-based doublet chemotherapy

gemcitabine + platinum

Description:

Patients with gemcitabine + platinum doublet, with or without additional targeted agents

Treatment:

Drug: Any platinum-based doublet chemotherapy

taxanes + platinum

Description:

Patients with taxanes + platinum doublet, with or without additional targeted agents

Treatment:

Drug: Any platinum-based doublet chemotherapy

vinorelbine + platinum

Description:

Patients with vinorelbine + platinum doublet, with or without additional targeted agents

Treatment:

Drug: Any platinum-based doublet chemotherapy

others + platinum

Description:

Patients with other platinum-based doublet, with or without additional targeted agents

Treatment:

Drug: Any platinum-based doublet chemotherapy